What is Zacks Research’s Forecast for Bruker Q1 Earnings?

Bruker Co. (NASDAQ:BRKR) – Zacks Research lowered their Q1 2025 EPS estimates for shares of Bruker in a report issued on Thursday, March 6th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $0.44 for the quarter, down from their previous forecast of $0.52. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q3 2025 earnings at $0.70 EPS, FY2025 earnings at $2.67 EPS, Q2 2026 earnings at $0.70 EPS, Q3 2026 earnings at $0.82 EPS, FY2026 earnings at $3.11 EPS and FY2027 earnings at $3.60 EPS.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%.

Other analysts have also issued reports about the company. Bank of America raised their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Barclays decreased their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research report on Thursday, December 5th. Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Monday, February 24th. Finally, Stifel Nicolaus dropped their price objective on Bruker from $70.00 to $57.00 and set a “hold” rating for the company in a report on Friday, February 14th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $48.20 on Friday. The company has a market cap of $7.31 billion, a P/E ratio of 63.42, a P/E/G ratio of 2.16 and a beta of 1.16. The business has a fifty day simple moving average of $55.37 and a 200-day simple moving average of $59.28. Bruker has a 52 week low of $45.29 and a 52 week high of $94.86. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Monday, March 17th. Bruker’s dividend payout ratio is presently 26.32%.

Institutional Investors Weigh In On Bruker

A number of large investors have recently modified their holdings of the stock. True Wealth Design LLC raised its stake in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 510 shares during the period. Eagle Bay Advisors LLC grew its holdings in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. increased its stake in Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after buying an additional 248 shares during the period. GAMMA Investing LLC lifted its holdings in Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company’s stock worth $75,000 after buying an additional 412 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after buying an additional 196 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.